Analysts Issue Forecasts for BioCardia FY2026 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – HC Wainwright cut their FY2026 earnings estimates for BioCardia in a research report issued on Thursday, March 26th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.71) per share for the year, down from their prior forecast of ($0.69). The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.14.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioCardia has a consensus rating of “Hold” and a consensus target price of $25.00.

BioCardia Stock Performance

BCDA stock opened at $1.16 on Monday. The firm has a market cap of $12.69 million, a PE ratio of -0.90 and a beta of 0.60. BioCardia has a 1 year low of $1.00 and a 1 year high of $3.20. The company has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.33.

Hedge Funds Weigh In On BioCardia

Institutional investors have recently modified their holdings of the company. DRW Securities LLC acquired a new stake in shares of BioCardia in the fourth quarter worth $72,000. Geode Capital Management LLC grew its stake in BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after buying an additional 27,263 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in BioCardia in the 2nd quarter valued at $40,000. Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.